Vanguard Personalized Indexing Management LLC Sells 2,763 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Vanguard Personalized Indexing Management LLC lowered its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.5% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 105,906 shares of the biopharmaceutical company’s stock after selling 2,763 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Gilead Sciences were worth $7,263,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of GILD. Manning & Napier Advisors LLC bought a new position in shares of Gilead Sciences in the second quarter valued at about $25,328,000. Eagle Asset Management Inc. boosted its holdings in shares of Gilead Sciences by 23.6% during the fourth quarter. Eagle Asset Management Inc. now owns 317,539 shares of the biopharmaceutical company’s stock worth $25,724,000 after acquiring an additional 60,697 shares during the period. GSA Capital Partners LLP acquired a new position in shares of Gilead Sciences in the first quarter valued at approximately $462,000. Brookstone Capital Management increased its stake in shares of Gilead Sciences by 751.1% during the first quarter. Brookstone Capital Management now owns 127,258 shares of the biopharmaceutical company’s stock worth $9,322,000 after purchasing an additional 112,305 shares during the period. Finally, Comerica Bank lifted its holdings in Gilead Sciences by 10.7% during the 4th quarter. Comerica Bank now owns 329,990 shares of the biopharmaceutical company’s stock worth $26,733,000 after purchasing an additional 31,849 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Royal Bank of Canada increased their price objective on Gilead Sciences from $72.00 to $74.00 and gave the stock a “sector perform” rating in a research report on Wednesday, September 4th. Robert W. Baird reaffirmed a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a report on Thursday, June 20th. Evercore ISI upgraded Gilead Sciences to a “strong-buy” rating in a research note on Friday, August 9th. Raymond James upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price objective on the stock in a research note on Monday, July 8th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $70.00 target price on shares of Gilead Sciences in a research report on Monday. Twelve equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $82.06.

Gilead Sciences Trading Up 1.0 %

Shares of Gilead Sciences stock opened at $83.89 on Thursday. The firm has a market capitalization of $104.51 billion, a PE ratio of 233.03, a price-to-earnings-growth ratio of 2.80 and a beta of 0.18. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18. The firm’s 50 day moving average is $76.40 and its 200 day moving average is $71.09. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $87.86.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The company had revenue of $6.95 billion during the quarter, compared to the consensus estimate of $6.64 billion. Equities research analysts forecast that Gilead Sciences, Inc. will post 3.78 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be paid a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.67%. The ex-dividend date is Friday, September 13th. Gilead Sciences’s payout ratio is 855.56%.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the transaction, the insider now owns 96,380 shares in the company, valued at approximately $6,614,559.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the sale, the insider now owns 114,979 shares of the company’s stock, valued at $8,506,146.42. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the transaction, the insider now directly owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The disclosure for this sale can be found here. Over the last three months, insiders have sold 36,847 shares of company stock worth $3,002,940. Insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.